Analysis Ginkgo Bioworks Holdings, Inc. (DNA)
5/30/2024
Analysis of Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. is a synthetic biology company that designs custom microbes for customers across multiple industries, including agriculture, pharmaceuticals, and food. The company went public through a SPAC merger in 2021 and has since been focused on expanding its capabilities and partnerships.From the provided data, it seems that the stock of Ginkgo Bioworks Holdings, Inc. (DNA) has been experiencing a downward trend in recent days. The Relative Strength Index (RSI) values have been below 50, indicating a bearish sentiment in the market. Additionally, the Moving Average Convergence Divergence (MACD) indicator has been negative, suggesting a potential bearish signal.
It is important to note that stock analysis should not be based solely on historical data, as market conditions and company-specific factors can change rapidly. Investors interested in Ginkgo Bioworks Holdings, Inc. should consider conducting a more comprehensive analysis that includes fundamental, technical, and market sentiment factors before making any investment decisions.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a significant increase in sales from 2020 to 2022, followed by a slight decrease in 2023.
- Overall, there has been a positive revenue growth trend over the past four years, indicating the company's ability to generate increasing sales.
- It would be beneficial to further analyze the factors contributing to the fluctuations in revenue to make informed business decisions.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with a high price-to-book ratio and price-to-sales ratio.
The stock price summary includes beta, moving averages, and the range of prices over the past year.
Lastly, dividends and splits information shows the company's dividend history, payout ratio, and dividend yield metrics. The company has a regular dividend payment schedule and has undergone a stock split in the past.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
5. Investing activities include the sale and purchase of investments, capital expenditures, and acquisitions.
6. The end cash position has also been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in expected earnings per share for both the upcoming quarters and the next two fiscal years. The average estimates show growth compared to the previous year's EPS figures, indicating optimism among analysts regarding the company's performance.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the historical average. However, the company is still projected to experience double-digit growth over the next 5 years according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is below both the average and median forecast, indicating that there is potential upside according to the analysts' predictions.
MACD of DNA
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
